Sarepta Therapeutics, Inc. (SRPT) Recent Ownership Changes

Maricruz Casares
Enero 13, 2018

Brouwer & Janachowski Llc increased its stake in Facebook Inc (FB) by 58.22% based on its latest 2017Q3 regulatory filing with the SEC. To cut down amount of noise on price chart, shares of firm has 20 days moving average price of -2.24% from last close price of 54.02 and act as support or resistance of price limit. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company's stock valued at $49,858,000 after buying an additional 207,810 shares during the last quarter. The stock increased 0.09% or $0.15 during the last trading session, reaching $174.5.

HC Wainwright set a $75.00 price objective on Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Wednesday, January 3rd. It has outperformed by 80.12% the S&P500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Following the transaction, the senior vice president now directly owns 37,045 shares of the company's stock, valued at $2,037,475. The institutional investor held 135,500 shares of the public utilities company at the end of 2017Q3, valued at $2.56M, up from 114,500 at the end of the previous reported quarter. Brouwer & Janachowski Llc who had been investing in Facebook Inc for a number of months, seems to be bullish on the $545.62B market cap company.

Many analysts are providing their Estimated Earnings analysis for Sarepta Therapeutics, Inc. and for the current quarter 15 analysts have projected that the stock could give an Average Earnings estimate of $-0.32/share. About 46,223 shares traded. Vipshop Holdings Limited (NYSE:VIPS) has risen 27.19% since January 11, 2017 and is uptrending. It has underperformed by 22.69% the S&P500. The firm shows the market capitalization of $3.61 Billion. (NASDAQ:SRPT) to report earnings on February, 27.

Analysts await Salesforce.com, inc.

Among 9 analysts covering Seacoast Banking Co. of Florida (NASDAQ:SBCF), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 100% are positive. Radcom Ltd had 7 analyst reports since February 18, 2016 according to SRatingsIntel. The stock has "Buy" rating by Zacks on Monday, August 17. As per Wednesday, June 28, the company rating was maintained by Credit Suisse. This is in contrast to SRPT which will have a positive growth at a -0.20% annual rate. On Thursday, October 26 the stock rating was maintained by Needham with "Buy". Wells Fargo downgraded CenturyLink, Inc. Shares for $43.15 million were sold by COOK TIMOTHY D on Thursday, August 24. (NASDAQ:FB) on Monday, July 17 with "Buy" rating. RBC Capital Markets has "Sector Perform" rating and $15.0 target. On Wednesday, January 4 the stock rating was maintained by Morgan Stanley with "Equal-Weight".

More news: Schlumberger (SLB) Downgraded by ValuEngine

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.13, from 1.08 in 2017Q2. It improved, as 52 investors sold AAPL shares while 1034 reduced holdings. 22 funds opened positions while 45 raised stakes. Emerald Mutual Fund Advisers owns 716,772 shares. Bokf Na accumulated 0.06% or 116,712 shares. Jane Street Gru Ltd Llc holds 67,194 shares or 0.01% of its portfolio. Capital Investment Of America stated it has 0.06% of its portfolio in Apple Inc. Horizon Kinetics Llc invested in 13,117 shares. Gotham Asset Management Ltd Co has 9,268 shares for 0.01% of their portfolio. Its down 72.64% from 121,700 shares previously. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0.08% in CenturyLink, Inc. Sarepta Therapeutics Inc now has $3.49B valuation. (NYSE:CTL) for 2.11M shares. The debt ratio of VIAB is 1.84 compared to 0.04 for SRPT. Clovis Oncology Inc. (NASDAQ:CLVS) was reduced too. (NASDAQ:SRPT). Pub Employees Retirement Association Of Colorado holds 0% or 10,545 shares in its portfolio. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company's stock valued at $193,000 after acquiring an additional 2,493 shares during the period. (NASDAQ:AAPL). Arrow holds 3.34% of its portfolio in Apple Inc. (NYSE:CTL) or 540,400 shares.

Hollencrest Securities Llc, which manages about $1.14 billion and $722.84M US Long portfolio, upped its stake in Pimco Active Bond Etf (BOND) by 7,319 shares to 70,260 shares, valued at $7.50M in 2017Q3, according to the filing. Robert W. Baird reissued a buy rating and issued a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th.

Investors sentiment increased to 2.88 in Q3 2017. Its down 0.57, from 2.17 in 2017Q2. It increased, as 24 investors sold SRPT shares while 27 reduced holdings.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sg Americas Ltd reported 8,300 shares or 0% of all its holdings. About 1.63M shares traded. Sarepta Therapeutics Inc's 3.40% rise today is critical to its technical outlook.

In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, November 30th. Winslow Capital Management Ltd Com reported 3.33 million shares. Eam Invsts Limited Liability Corp has 61,155 shares for 0.37% of their portfolio. Essex Finance Serv holds 3.66% of its portfolio in Apple Inc. 32,906 were accumulated by Nationwide Fund Advisors. Oppenheimer also issued estimates for Sarepta Therapeutics' Q4 2017 earnings at ($0.26) EPS, FY2018 earnings at ($1.27) EPS, FY2019 earnings at ($0.64) EPS and FY2020 earnings at $2.84 EPS. (NASDAQ:SRPT). Citigroup has 0% invested in Sarepta Therapeutics, Inc.

Otros informes por

Discuta este artículo

SIGUE NUESTRO PERIÓDICO